利妥昔单抗注射用冻干粉治疗复发或难治性大 B 细胞淋巴瘤。
Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
机构信息
Department of Medicine, Division of Hematology/Oncology & the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60208, USA.
出版信息
Future Oncol. 2023 Jan;19(1):19-28. doi: 10.2217/fon-2022-0774. Epub 2023 Jan 18.
Lisocabtagene maraleucel (liso-cel) is one of the three US FDA-approved chimeric antigen receptor T-cell therapies for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). TRANSCEND is the landmark trial that led to the approval of liso-cel in the third-line setting for R/R diffuse LBCL, primary mediastinal B-cell lymphoma, follicular lymphoma grade 3B and transformed lymphoma. The TRANSFORM and PILOT studies evaluated the use of liso-cel in the second-line treatment of R/R LBCL. This review details the structure and manufacturing process of liso-cel that make it distinct from other approved chimeric antigen receptor constructs, outlines results from landmark trials of liso-cel in LBCL and discusses liso-cel toxicity.
利妥昔单抗注射用细胞（liso-cel）是美国食品药品监督管理局（FDA）批准的三种嵌合抗原受体 T 细胞疗法之一，用于治疗复发/难治性（R/R）大 B 细胞淋巴瘤（LBCL）。TRANSCEND 是一项具有里程碑意义的临床试验，该试验促使 liso-cel 在三线治疗 R/R 弥漫性大 B 细胞淋巴瘤、原发性纵隔 B 细胞淋巴瘤、滤泡性淋巴瘤 3B 级和转化性淋巴瘤中获得批准。TRANSFORM 和 PILOT 研究评估了 liso-cel 在 R/R LBCL 二线治疗中的应用。本文详细介绍了 liso-cel 的结构和制造工艺，使其有别于其他已批准的嵌合抗原受体构建物，概述了 liso-cel 在 LBCL 中的标志性临床试验结果，并讨论了 liso-cel 的毒性。
Zotero 插件